Armata Pharmaceuticals
ARMP
24 hedge funds and large institutions have $427K invested in Armata Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 4 closing their positions.
886% more capital inflows, than outflows
Capital inflows: $462K | Capital outflows: $46.9K
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
1.4% more ownership
Funds ownership: 5.05% → 6.45% (+1.4%)
0% more funds holding
Funds holding: 24 → 24 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$284K |
| 2 |
Renaissance Technologies
New York
|
+$76.1K |
| 3 |
Panagora Asset Management
Boston,
Massachusetts
|
+$34.2K |
| 4 |
Paloma Partners
Greenwich,
Connecticut
|
+$16.3K |
| 5 |
Virtu Financial
New York
|
+$14.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$15.8K |
| 2 |
Synovus Financial
Columbus,
Georgia
|
-$15K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
-$10K |
| 4 |
Stratos Wealth Partners
Beachwood,
Ohio
|
-$5K |
| 5 |
Wilbanks Smith & Thomas Asset Management
Norfolk,
Virginia
|
-$1K |
ARMP Hedge Fund Activity: Q4 2018 in Review
24 of the 4,506 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q4 2018, worth a combined $427K — down 49% from $843K a quarter earlier.
Fund positioning in ARMP was balanced in Q4 2018: 4 funds opened new positions, 4 closed out, 8 added to existing stakes and 2 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $284K. The largest seller was Vanguard Group, cutting an estimated $15.8K.
- 24 institutional investors held Armata Pharmaceuticals (ARMP) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $427K of Armata Pharmaceuticals stock for Q4 2018, down 49% quarter-over-quarter.
- 4 funds opened new Armata Pharmaceuticals positions in Q4 2018 and 4 closed out, a net change of 0 holders.
- The largest Armata Pharmaceuticals buyer in Q4 2018 was Sabby Management, an estimated $284K added.
- The largest Armata Pharmaceuticals seller in Q4 2018 was Vanguard Group, an estimated $15.8K sold.
Based on aggregated 13F filings for Q4 2018.